Work

Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy

Year: 2015

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.mel2014-b16

Authors: Georgina Long, Reinhard Dummer, Keith Flaherty, Dirk Schadendorf, Petr Arenberger, Lev Demidov, Anna Maria Di Giacomo, Mario Mandalà, Giovanni Rangoni, Pascal Wolter, Naoya Yamazaki, James Ford, Ernesto Wasserman, Marine Weill, Paolo Ascierto

Institutions: The University of Sydney, Melanoma Institute Australia, University Hospital Zurich, Massachusetts General Hospital, Essen University Hospital, Charles University, Russian Cancer Research Center NN Blokhin, University of Siena, Ospedale Papa Giovanni XXIII, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, KU Leuven, Novartis (United States), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1542660348

Cites:

Cited by: 1

Related to: 10